Burkitt's lymphoma: The Rosetta Stone deciphering Epstein-Barr virus biology

Seminars in Cancer Biology

Volumn 19, Issue 6, 2009, Pages 377-388

  Rowe, Martin ^a   Kelly, Gemma L ^a   Bell, Andrew I ^a   Rickinson, Alan B ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Apoptosis; Burkitt's lymphoma; c myc; Cancer pathogenesis; Epstein Barr virus

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 2; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; MICRORNA; MYC PROTEIN; UNTRANSLATED RNA;

B LYMPHOCYTE; BURKITT LYMPHOMA; CARCINOGENICITY; CELL SURVIVAL; CELLULAR IMMUNITY; CHROMOSOME TRANSLOCATION; EPSTEIN BARR VIRUS; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOMODULATION; LATENT VIRUS INFECTION; MALARIA; NONHUMAN; REVIEW; RNA TRANSCRIPTION; VIRUS CARCINOGENESIS; VIRUS CELL INTERACTION; VIRUS LATENCY;

ANIMALS; BURKITT LYMPHOMA; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS;

EID: 70749143567     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2009.07.004     Document Type: Review

References (184)

1. Burkitt D. A sarcoma involving the jaws in African children. Br J Surg 46 (1958) 218-223
2. Burkitt D. A children's cancer dependent on climatic factors. Nature 194 (1962) 232-234
3. Epstein M.A., Achong B.G., and Barr Y.M. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet i (1964) 702-703
4. Rickinson A.B., and Kieff E. Epstein-Barr virus. In: Knipe D.M., and Howley P.M. (Eds). Fields virology (2007), Walters Kluwer/Lippincott, Williams & Wilkins, Philadelphia 2655-2700
5. Burkitt D.P. Etiology of Burkitt's lymphoma-an alternative hypothesis to a vectored virus. J Natl Cancer Inst 42 (1969) 19-28
6. Dalla-Favera R., Bregni M., Erikson J., Patterson D., Gallo R.C., and Croce C.M. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 79 (1982) 7824-7827
7. Lenoir G.M., Preud'homme J.L., Bernheim A., and Berger R. Correlation between immunoglobulin light chain expression and variant translocation in Burkitt's lymphoma. Nature 298 (1982) 474-476
8. Taub R., Kirsch I., Morton C., Lenoir G., Swan D., Tronick S., et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci USA 79 (1982) 7837-7841
9. de-The G. The Epstein-Barr virus (EBV): a Rosetta Stone for understanding the role of viruses in immunopathological disorders and in human carcinogenesis. Biomed Pharmacother 39 (1985) 49-51
10. Henle W., Diehl V., Kohn G., Zur Hausen H., and Henle G. Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells. Science 157 (1967) 1064-1065
11. Pope J.H., Horne M.K., and Scott W. Transformation of foetal human keukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus. Int J Cancer 3 (1968) 857-866
12. de The G., Geser A., Day N.E., Tukei P.M., Williams E.H., Beri D.P., et al. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. Nature 274 (1978) 756-761
13. Geser A., de The G., Lenoir G., Day N.E., and Williams E.H. Final case reporting from the Ugandan prospective study of the relationship between EBV and Burkitt's lymphoma. Int J Cancer 29 (1982) 397-400
14. Lindahl T., Klein G., Reedman B.M., Johansson B., and Singh S. Relationship between Epstein-Barr virus (EBV) DNA and the EBV-determined nuclear antigen (EBNA) in Burkitt lymphoma biopsies and other lymphoproliferative malignancies. Int J Cancer 13 (1974) 764-772
15. Nonoyama M., Huang C.H., Pagano J.S., Klein G., and Singh S. DNA of Epstein-Barr virus detected in tissue of Burkitt's lymphoma and nasopharyngeal carcinoma. Proc Natl Acad Sci USA 70 (1973) 3265-3268
16. Zur Hausen H., Schulte-Holthausen H., Klein G., Henle W., Henle G., Clifford P., et al. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature (Lond) 228 (1970) 1056-1058
17. Rowe D.T., Rowe M., Evan G.I., Wallace L.E., Farrell P.J., and Rickinson A.B. Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells. EMBO J 5 (1986) 2599-2607
18. Rowe M., Rowe D.T., Gregory C.D., Young L.S., Farrell P.J., Rupani H., et al. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J 6 (1987) 2743-2751
19. Masucci M.G., Torsteinsdottir S., Colombani J., Brautbar C., Klein E., and Klein G. Down-regulation of class-I HLA antigens and of the Epstein-Barr virus (EBV)-encoded latent membrane protein (LMP) in Burkitt's lymphoma lines. Proc Natl Acad Sci USA 84 (1987) 4567-4572
20. Thomas J.A., Hotchin N.A., Allday M.J., Amlot P., Rose M., Yacoub M., et al. Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals. Transplantation 49 (1990) 944-953
21. Young L., Alfieri C., Hennessey K., Evans H., O'Hara C., Anderson K.C., et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. New Engl J Med 321 (1989) 1080-1085
22. Rowe M., Young L.S., Crocker J., Stokes H., Henderson S., and Rickinson A.B. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med 173 (1991) 147-158
23. Gregory C.D., Rowe M., and Rickinson A.B. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt lymphoma cell line. J Gen Virol 71 (1990) 1481-1495
24. Rowe M., Lear A., Croom-Carter D., Davies A.H., and Rickinson A.B. Three pathways of Epstein-Barr virus (EBV) gene activation from EBNA1-positive latency in B lymphocytes. J Virol 66 (1992) 122-131
25. Kelly G., Bell A., and Rickinson A. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat Med 8 (2002) 1098-1104
26. Kelly G.L., Milner A.E., Tierney R.J., Croom-Carter D.S., Altmann M., Hammerschmidt W., et al. Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis. J Virol 79 (2005) 10709-10717
27. Kelly G.L., Long H.M., Stylianou J., Thomas W.A., Leese A., Bell A.I., et al. An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link. PLoS Pathog 5 (2009) e1000341
28. Pfeffer S., Sewer A., Lagos-Quintana M., Sheridan R., Sander C., Grasser F.A., et al. Identification of microRNAs of the herpesvirus family. Nat Methods 2 (2005) 269-276
29. Pfeffer S., Zavolan M., Grasser F.A., Chien M., Russo J.J., Ju J., et al. Identification of virus-encoded microRNAs. Science 304 (2004) 734-736
30. Cai X., Schafer A., Lu S., Bilello J.P., Desrosiers R.C., Edwards R., et al. Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog 2 (2006) e23
31. Grundhoff A., Sullivan C.S., and Ganem D. A combined computational and microarray-based approach identifies novel microRNAs encoded by human gamma-herpesviruses. RNA 12 (2006) 733-750
32. Schaefer B.C., Strominger J.L., and Speck S.H. Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines. Proc Natl Acad Sci USA 92 (1995) 10565-10569
33. Nonkwelo C., Skinner J., Bell A., Rickinson A., and Sample J. Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein. J Virol 70 (1996) 623-627
34. Sample J., Hummel M., Braun D., Birkenbach M., and Kieff E. Nucleotide sequences of mRNAs encoding Epstein-Barr virus nuclear proteins: a probable transcriptional initiation site. Proc Natl Acad Sci USA 83 (1986) 5096-5100
35. Speck S.H., Pfitzner A., and Strominger J.L. An Epstein-Barr virus transcript from a latently infected, growth-transformed B-cell line encodes a highly repetitive polypeptide. Proc Natl Acad Sci USA 83 (1986) 9298-9302
36. Bodescot M., and Perricaudet M. Epstein-Barr virus mRNAs produced by alternative splicing. Nucleic Acids Res 14 (1986) 7103-7114
37. Woisetschlaeger M., Yandava C.N., Furmanski L.A., Strominger J.L., and Speck S.H. Promoter switching in Epstein-Barr virus during the initial stages of infection of B lymphocytes. Proc Natl Acad Sci USA 87 (1990) 1725-1729
38. Fåhraeus R., Li-Fu H., Ernberg I., Finke J., Rowe M., Klein G., et al. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 42 (1988) 329-338
39. Young L., Dawson C., Clark D., Rupani H., Busson P., Tursz T., et al. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 69 (1988) 1051-1065
40. Gilligan K., Sato H., Rajadural P., Busson P., Young L., Rickinson A., et al. Novel transcription from the Epstein-Barr virus terminal EcoRI fragment, DIJhet, in a nasopharyngeal carcinoma. J Virol 64 (1990) 4948-4956
41. Imai S., Koizumi S., Sugiura M., Tokunaga M., Uemura Y., Yamamoto N., et al. Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci USA 91 (1994) 9131-9135
42. Sugiura M., Imai S., Tokunaga M., Koizumi S., Uchizawa M., Okamoto K., et al. Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells. Br J Cancer 74 (1996) 625-631
43. Niedobitek G., Deacon E.M., Young L.S., Herbst H., Hamilton-Dutoit S.J., and Pallesen G. Epstein-Barr virus gene expression in Hodgkin's disease. Blood 78 (1991) 1628-1629
44. Pallesen G., Sandvej K., Hamilton-Dutoit S.J., Rowe M., and Young L.S. Activation of Epstein-Barr virus replication in Hodgkin and Reed-Sternberg cells. Blood 78 (1991) 1162-1165
45. Chiang A.K., Tao Q., Srivastava G., and Ho F.C. Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease. Int J Cancer 68 (1996) 285-290
46. Tierney R., Nagra J., Hutchings I., Shannon-Lowe C., Altmann M., Hammerschmidt W., et al. Epstein-Barr virus exploits BSAP/Pax5 to achieve the B-cell specificity of its growth-transforming program. J Virol 81 (2007) 10092-10100
47. Johannsen E., Koh E., Mosialos G., Tong X., Kieff E., and Grossman S.R. Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by Jk and PU.1. J Virol 69 (1995) 253-262
48. Wang F., Tsang S.F., Kurilla M.G., Cohen J.I., and Kieff E. Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J Virol 64 (1990) 3407-3416
49. Zimber-Strobl U., Suentzenich K.O., Laux G., Eick D., Cordier M., Calender A., et al. Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene. J Virol 65 (1991) 415-423
50. Sjoblom A., Jansson A., Yang W., Lain S., Nilsson T., and Rymo L. PU box-binding transcription factors and a POU domain protein cooperate in the Epstein-Barr virus (EBV) nuclear antigen 2-induced transactivation of the EBV latent membrane protein 1 promoter. J Gen Virol 76 Pt 11 (1995) 2679-2692
51. Jansson A., Johansson P., Yang W., Palmqvist L., Sjoblom-Hallen A., and Rymo L. Role of a consensus AP-2 regulatory sequence within the Epstein-Barr virus LMP1 promoter in EBNA2 mediated transactivation. Virus Genes 35 (2007) 203-214
52. Chen H., Lee J.M., Zong Y., Borowitz M., Ng M.H., Ambinder R.F., et al. Linkage between STAT regulation and Epstein-Barr virus gene expression in tumors. J Virol 75 (2001) 2929-2937
53. Tsai C.N., Lee C.M., Chien C.K., Kuo S.C., and Chang Y.S. Additive effect of Sp1 and Sp3 in regulation of the ED-L1E promoter of the EBV LMP 1 gene in human epithelial cells. Virology 261 (1999) 288-294
54. Sadler R.H., and Raab-Traub N. The Epstein-Barr virus 3.5-kilobase latent membrane protein 1 mRNA initiates from a TATA-Less promoter within the first terminal repeat. J Virol 69 (1995) 4577-4581
55. Johansson P., Jansson A., Ruetschi U., and Rymo L. Nuclear factor-kappaB binds to the Epstein-Barr Virus LMP1 promoter and upregulates its expression. J Virol 83 (2009) 1393-1401
56. Goormachtigh G., Ouk T.S., Mougel A., Tranchand-Bunel D., Masy E., Le Clorennec C., et al. Autoactivation of the Epstein-Barr virus oncogenic protein LMP1 during type II latency through opposite roles of the NF-kappaB and JNK signaling pathways. J Virol 80 (2006) 7382-7393
57. Heussinger N., Buttner M., Ott G., Brachtel E., Pilch B.Z., Kremmer E., et al. Expression of the Epstein-Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopharyngeal carcinoma. J Pathol 203 (2004) 696-699
58. Stewart S., Dawson C.W., Takada K., Curnow J., Moody C.A., Sixbey J.W., et al. Epstein-Barr virus-encoded LMP2A regulates viral and cellular gene expression by modulation of the NF-kappaB transcription factor pathway. Proc Natl Acad Sci USA 101 (2004) 15730-15735
59. Kelly G.L., Milner A.E., Baldwin G.S., Bell A.I., and Rickinson A.B. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proc Natl Acad Sci USA 103 (2006) 14935-14940
60. Cleary M.L., Smith S.D., and Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 47 (1986) 19-28
61. Henderson S., Huen D., Rowe M., Dawson C., Johnson G., and Rickinson A. Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc Natl Acad Sci USA 90 (1993) 8479-8483
62. Walling D.M., Clark N.M., Markovitz D.M., Frank T.S., Braun D.K., Eisenberg E., et al. Epstein-Barr virus coinfection and recombination in non-human immunodeficiency virus-associated oral hairy leukoplakia. J Infect Dis 171 (1995) 1122-1130
63. Walling D.M., Perkins A.G., Webster-Cyriaque J., Resnick L., and Raab-Traub N. The Epstein-Barr virus EBNA-2 gene in oral hairy leukoplakia: strain variation, genetic recombination, and transcriptional expression. J Virol 68 (1994) 7918-7926
64. Gregory C.D., Murray R.J., Edwards C.F., and Rickinson A.B. Down regulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumour cell escape from virus-specific T cell surveillance. J Exp Med 167 (1988) 1811-1824
65. Niedobitek G., Agathanggelou A., Rowe M., Jones E.L., Jones D.B., Turyaguma P., et al. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma. Blood 86 (1995) 659-665
66. Floettmann E., Ward K., Rickinson A.B., and Rowe M. Cytostatic effect of Epstein-Barr virus Latent Membrane Protein-1 (LMP1) analysed using tetracycline-regulated expression. Virology 223 (1996) 29-40
67. Rowe M., Khanna R., Jacob C.A., Argaet V., Kelly A., Powis S., et al. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein Barr Virus Latent Membrane protein-1: coordinate upregulation of peptide transporters and HLA Class I antigen expression. Eur J Immunol 25 (1995) 1374-1384
68. Wei M.X., and Ooka T. A transforming function of the BARF1 gene encoded by Epstein-Barr virus. EMBO J 8 (1989) 2897-2903
69. Wei M.X., Moulin J.C., Decaussin G., Berger F., and Ooka T. Expression and tumorigenicity of the Epstein-Barr virus BARF1 gene in human Louckes B-lymphocyte cell line. Cancer Res 54 (1994) 1843-1848
70. Seto E., Yang L., Middeldorp J., Sheen T.S., Chen J.Y., Fukayama M., et al. Epstein-Barr virus (EBV)-encoded BARF1 gene is expressed in nasopharyngeal carcinoma and EBV-associated gastric carcinoma tissues in the absence of lytic gene expression. J Med Virol 76 (2005) 82-88
71. Fiorini S., and Ooka T. Secretion of Epstein-Barr virus-encoded BARF1 oncoprotein from latently infected B cells. Virol J 5 (2008) 70
72. Xue S.A., Labrecque L.G., Lu Q.L., Ong S.K., Lampert I.A., Kazembe P., et al. Promiscuous expression of Epstein-Barr virus genes in Burkitt's lymphoma from the central African country Malawi. Int J Cancer 99 (2002) 635-643
73. Decaussin G., Sbih-Lammali F., de Turenne-Tessier M., Bouguermouh A., and Ooka T. Expression of BARF1 gene encoded by Epstein-Barr virus in nasopharyngeal carcinoma biopsies. Cancer Res 60 (2000) 5584-5588
74. zur Hausen A., Brink A.A., Craanen M.E., Middeldorp J.M., Meijer C.J., and van den Brule A.J. Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarcinomas: expression of the transforming BARF1 gene. Cancer Res 60 (2000) 2745-2748
75. Thorley-Lawson D.A. Epstein-Barr virus: exploiting the immune system. Nature Rev Immunol 1 (2001) 75-82
76. Bell A.I., Groves K., Kelly G.L., Croom-Carter D., Hui E., Chan A.T., et al. Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays. J Gen Virol 87 (2006) 2885-2890
77. Lerner M.R., Andrews N.C., Miller G., and Steitz J.A. Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus. Proc Natl Acad Sci USA 78 (1981) 805-809
78. Rymo L. Identification of transcribed regions of Epstein-Barr virus DNA in Burkitt lymphoma-derived cells. J Virol 32 (1979) 8-18
79. Rosa M.D., Gottlieb E., Lerner M.R., and Steitz J.A. Striking similarities are exhibited by two small Epstein-Barr virus-encoded ribonucleic acids and the adenovirus-associated ribonucleic acids VAI and VAII. Mol Cell Biol 1 (1981) 785-796
80. Gilligan K., Rajadurai P., Resnick L., and Raab-Traub N. Epstein-Barr virus small nuclear RNAs are not expressed in permissively infected cells in AIDS-associated leukoplakia. Proc Natl Acad Sci USA 87 (1990) 8790-8794
81. Hitt M.M., Allday M.J., Hara T., Karran L., Jones M.D., Busson P., et al. EBV gene expression in an NPC-related tumour. EMBO J 8 (1989) 2639-2651
82. Al-Mozaini M., Bodelon G., Karstegl C.E., Jin B., Al-Ahdal M., and Farrell P.J. Epstein-Barr virus BART gene expression. J Gen Virol 90 (2009) 307-316
83. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 (2004) 281-297
84. Xing L., and Kieff E. Epstein-Barr virus BHRF1 micro- and stable RNAs during latency III and after induction of replication. J Virol 81 (2007) 9967-9975
85. Raab-Traub N., Dambaugh T., and Kieff E. DNA of Epstein-Barr virus VIII: B95-8, the previous prototype, is an unusual deletion derivative. Cell 22 (1980) 257-267
86. Pratt Z.L., Kuzembayeva M., Sengupta S., and Sugden B. The microRNAs of Epstein-Barr Virus are expressed at dramatically differing levels among cell lines. Virology 386 (2009) 387-397
87. Edwards R.H., Marquitz A.R., and Raab-Traub N. Epstein-Barr virus BART microRNAs are produced from a large intron prior to splicing. J Virol 82 (2008) 9094-9106
88. Cosmopoulos K., Pegtel M., Hawkins J., Moffett H., Novina C., Middeldorp J., et al. Comprehensive profiling of Epstein-Barr virus microRNAs in nasopharyngeal carcinoma. J Virol 83 (2009) 2357-2367
89. Delecluse H.J., and Hammerschmidt W. The genetic approach to the Epstein-Barr virus: from basic virology to gene therapy. Mol Pathol 53 (2000) 270-279
90. Kieff E., and Rickinson A.B. Epstein-Barr virus and its replication. In: Knipe D.M., and Howley P.M. (Eds). Fields virology. 5th ed. (2007), Walters Kluwer/Lippincott, Williams & Wilkins, Philadelphia 2603-2654
91. Gregory C.D., Edwards C.F., Milner A., Wiels J., Lipinski M., Rowe M., et al. Isolation of a normal B cell subset with a Burkitt-like phenotype and transformation in vitro with Epstein-Barr virus. Int J Cancer 42 (1988) 213-220
92. Rochford R., Cannon M.J., and Moormann A.M. Endemic Burkitt's lymphoma: a polymicrobial disease?. Nat Rev Microbiol 3 (2005) 182-187
93. Moss D.J., Burrows S.R., Castelino D.J., Kane R.G., Pope J.H., Rickinson A.B., et al. A comparison of Epstein-Barr virus-specific T-cell immunity in malaria-endemic and -nonendemic regions of Papua New Guinea. Int J Cancer 31 (1983) 727-732
94. Whittle H.C., Brown J., Marsh K., Greenwood B.M., Seidelin P., Tighe H., et al. T-cell control of Epstein-Barr virus-infected B cells is lost during P. falciparum malaria. Nature 312 (1984) 449-450
95. Njie R., Bell A.I., Jia H., Croom-Carter D., Chaganti S., Hislop A.D., et al. The effects of acute malaria on Epstein-Barr virus (EBV) load and EBV-specific T cell immunity in Gambian children. J Infect Dis 199 (2009) 31-38
96. Moormann A.M., Chelimo K., Sumba P.O., Tisch D.J., Rochford R., and Kazura J.W. Exposure to holoendemic malaria results in suppression of Epstein-Barr virus-specific T cell immunosurveillance in Kenyan children. J Infect Dis 195 (2007) 799-808
97. Greenwood B.M., and Vick R.M. Evidence for malaria mitogen in human malaria. Nature 257 (1975) 592-594
98. Chene A., Donati D., Guerreiro-Cacais A.O., Levitsky V., Chen Q., Falk K.I., et al. A molecular link between malaria and Epstein-Barr virus reactivation. PLoS Pathog 3 (2007) e80
99. Moormann A.M., Chelimo K., Sumba O.P., Lutzke M.L., Ploutz-Snyder R., Newton D., et al. Exposure to holoendemic malaria results in elevated Epstein-Barr virus loads in children. J Infect Dis 191 (2005) 1233-1238
100. Rasti N., Falk K.I., Donati D., Gyan B.A., Goka B.Q., Troye-Blomberg M., et al. Circulating Epstein-Barr virus in children living in malaria-endemic areas. Scand J Immunol 61 (2005) 461-465
101. Yone C.L., Kube D., Kremsner P.G., and Luty A.J. Persistent Epstein-Barr viral reactivation in young African children with a history of severe Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 100 (2006) 669-676
102. Carbone A. Emerging pathways in the development of AIDS-related lymphomas. Lancet Oncol 4 (2003) 22-29
103. Ioachim H.L., Cronin W., Roy M., and Maya M. Persistent lymphadenopathies in people at high risk for HIV infection. Clinicopathologic correlations and long-term follow-up in 79 cases. Am J Clin Pathol 93 (1990) 208-218
104. Polack A., Hortnagel K., Pajic A., Christoph B., Baier B., Falk M., et al. c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1. Proc Natl Acad Sci USA 93 (1996) 10411-10416
105. Pajic A., Staege M.S., Dudziak D., Schuhmacher M., Spitkovsky D., Eissner G., et al. Antagonistic effects of c-myc and Epstein-Barr virus latent genes on the phenotype of human B cells. Int J Cancer 93 (2001) 810-816
106. Li Z., Van Calcar S., Qu C., Cavenee W.K., Zhang M.Q., and Ren B. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci USA 100 (2003) 8164-8169
107. Adhikary S., and Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 6 (2005) 635-645
108. Lindstrom M.S., and Wiman K.G. Role of genetic and epigenetic changes in Burkitt lymphoma. Semin Cancer Biol 12 (2002) 381-387
109. Hemann M.T., Bric A., Teruya-Feldstein J., Herbst A., Nilsson J.A., Cordon-Cardo C., et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436 (2005) 807-811
110. Egle A., Harris A.W., Bouillet P., and Cory S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci USA 101 (2004) 6164-6169
111. Clybouw C., McHichi B., Mouhamad S., Auffredou M.T., Bourgeade M.F., Sharma S., et al. EBV infection of human B lymphocytes leads to down-regulation of Bim expression: relationship to resistance to apoptosis. J Immunol 175 (2005) 2968-2973
112. Leao M., Anderton E., Wade M., Meekings K., and Allday M.J. Epstein-barr virus-induced resistance to drugs that activate the mitotic spindle assembly checkpoint in Burkitt's lymphoma cells. J Virol 81 (2007) 248-260
113. Ruf I.K., Rhyne P.W., Yang H., Borza C.M., Hutt-Fletcher L.M., Cleveland J.L., et al. Epstein-barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma. Mol Cell Biol 19 (1999) 1651-1660
114. Shimizu N., Tanabe-Tochikura A., Kuroiwa Y., and Takada K. Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV. J Virol 68 (1994) 6069-6073
115. Yates J., Warren N., Reisman D., and Sugden B. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci USA 81 (1984) 3806-3810
116. Reisman D., and Sugden B. trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1. Mol Cell Biol 6 (1986) 3838-3846
117. Yin Y., Manoury B., and Fahraeus R. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science 301 (2003) 1371-1374
118. Tellam J., Smith C., Rist M., Webb N., Cooper L., Vuocolo T., et al. Regulation of protein translation through mRNA structure influences MHC class I loading and T cell recognition. Proc Natl Acad Sci USA 105 (2008) 9319-9324
119. Kennedy G., Komano J., and Sugden B. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas. Proc Natl Acad Sci USA 100 (2003) 14269-14274
120. Sheng W., Decaussin G., Ligout A., Takada K., and Ooka T. Malignant transformation of Epstein-Barr virus-negative Akata cells by introduction of the BARF1 gene carried by Epstein-Barr virus. J Virol 77 (2003) 3859-3865
121. Komano J., Maruo S., Kurozumi K., Oda T., and Takada K. Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata. J Virol 73 (1999) 9827-9831
122. Ruf I.K., Lackey K.A., Warudkar S., and Sample J.T. Protection from interferon-induced apoptosis by Epstein-Barr virus small RNAs is not mediated by inhibition of PKR. J Virol 79 (2005) 14562-14569
123. Ruf I.K., Rhyne P.W., Yang C., Cleveland J.L., and Sample J.T. Epstein-Barr virus small RNAs potentiate tumorigenicity of Burkitt lymphoma cells independently of an effect on apoptosis. J Virol 74 (2000) 10223-10228
124. Samanta M., Iwakiri D., and Takada K. Epstein-Barr virus-encoded small RNA induces IL-10 through RIG-I-mediated IRF-3 signaling. Oncogene 27 (2008) 4150-4160
125. Samanta M., Iwakiri D., Kanda T., Imaizumi T., and Takada K. EB virus-encoded RNAs are recognized by RIG-I and activate signaling to induce type I IFN. EMBO J 25 (2006) 4207-4214
126. Sharp T.V., Schwemmle M., Jeffrey I., Laing K., Mellor H., Proud C.G., et al. Comparative analysis of the regulation of the interferon-inducible protein kinase PKR by Epstein-Barr virus RNAs EBER-1 and EBER-2 and adenovirus VAI RNA. Nucleic Acids Res 21 (1993) 4483-4490
127. Nanbo A., Inoue K., Adachi-Takasawa K., and Takada K. Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt's lymphoma. EMBO J 21 (2002) 954-965
128. Kitagawa N., Goto M., Kurozumi K., Maruo S., Fukayama M., Naoe T., et al. Epstein-Barr virus-encoded poly(A)(-) RNA supports Burkitt's lymphoma growth through interleukin-10 induction. EMBO J 19 (2000) 6742-6750
129. Henderson S., Rowe M., Gregory C., Wang F., Kieff E., and Rickinson A. Induction of bcl-2 expression by Epstein-Barr virus Latent Membrane Protein-1 protects infected B cells from programmed cell death. Cell 65 (1991) 1107-1115
130. Swaminathan S., Huneycutt B.S., Reiss C.S., and Kieff E. Epstein-Barr virus-encoded small RNAs (EBERs) do not modulate interferon effects in infected lymphocytes. J Virol 66 (1992) 5133-5136
131. Yajima M., Kanda T., and Takada K. Critical role of Epstein-Barr Virus (EBV)-encoded RNA in efficient EBV-induced B-lymphocyte growth transformation. J Virol 79 (2005) 4298-4307
132. Robertson E., and Kieff E. Reducing the complexity of the transforming Epstein-Barr virus genome to 64 kilobase pairs. J Virol 69 (1995) 983-993
133. Lo A.K., To K.F., Lo K.W., Lung R.W., Hui J.W., Liao G., et al. Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc Natl Acad Sci USA 104 (2007) 16164-16169
134. Barth S., Pfuhl T., Mamiani A., Ehses C., Roemer K., Kremmer E., et al. Epstein-Barr virus-encoded microRNA miR-BART2 down-regulates the viral DNA polymerase BALF5. Nucleic Acids Res 36 (2008) 666-675
135. Xia T., O'Hara A., Araujo I., Barreto J., Carvalho E., Sapucaia J.B., et al. EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. Cancer Res 68 (2008) 1436-1442
136. Choy E.Y., Siu K.L., Kok K.H., Lung R.W., Tsang C.M., To K.F., et al. An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. J Exp Med 205 (2008) 2551-2560
137. McCarthy N.J., Hazlewood S.A., Huen D.S., Rickinson A.B., and Williams G.T. The Epstein-Barr virus gene BHRF1, a homologue of the cellular oncogene Bcl-2, inhibits apoptosis induced by gamma radiation and chemotherapeutic drugs. Adv Exp Med Biol 406 (1996) 83-97
138. Kawanishi M., Tada-Oikawa S., and Kawanishi S. Epstein-Barr virus BHRF1 functions downstream of Bid cleavage and upstream of mitochondrial dysfunction to inhibit TRAIL-induced apoptosis in BJAB cells. Biochem Biophys Res Commun 297 (2002) 682-687
139. Altmann M., and Hammerschmidt W. Epstein-Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis. PLoS Biol 3 (2005) e404
140. Anderton E., Yee J., Smith P., Crook T., White R.E., and Allday M.J. Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma. Oncogene 27 (2008) 421-433
141. Rooney C.M., Rowe M., Wallace L.E., and Rickinson A.B. Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance. Nature 317 (1985) 629-631
142. Torsteinsdottir S., Masucci M.G., Ehlin-Henriksson B., Brautbar C., Ben Bassat H., Klein G., et al. Differentiation dependent sensitivity of human B-cell derived lines to major histocompatibility complex-restricted T-cell cytotoxicity. Proc Natl Acad Sci USA 83 (1986) 5620-5624
143. Murray R.J., Kurilla M.G., Brooks J.M., Thomas W.A., Rowe M., Kieff E., et al. Identification of target antigens for the human cytotoxic T-cell response to Epstein-Barr Virus (EBV)-implications for the immune control of EBV-positive malignancies. J Exp Med 176 (1992) 157-168
144. Khanna R., Burrows S.R., Kurilla M.G., Jacob C.A., Misko I.S., Sculley T.B., et al. Localization of Epstein-Barr Virus cytotoxic T-cell epitopes using recombinant vaccinia-implications for vaccine development. J Exp Med 176 (1992) 169-176
145. Levitskaya J., Coram M., Levitsky V., Imreh S., Steigerwald-Mullen P.M., Klein G., et al. The internal repeat region of the Epstein-Barr virus nuclear antigen-1 is a cis-acting inhibitor of antigen processing. Nature 375 (1995) 685-688
146. Lee S.P., Brooks J.M., Al-Jarrah H., Thomas W.A., Haigh T.A., Taylor G.S., et al. CD8 T cell recognition of endogenously expressed Epstein-Barr virus nuclear antigen 1. J Exp Med 199 (2004) 1409-1420
147. Tellam J., Connolly G., Green K.J., Miles J.J., Moss D.J., Burrows S.R., et al. Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1. J Exp Med 199 (2004) 1421-1431
148. Voo K.S., Fu T., Wang H.Y., Tellam J., Heslop H.E., Brenner M.K., et al. Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J Exp Med 199 (2004) 459-470
149. Imreh M., Zhang Q.-J., de Campos-Lima P.O., Imreh S., Krausa P., Brouning M., et al. Mechanisms of allele-selective down-regulation of HLA class I in Burkitt's lymphoma. Int J Cancer 62 (1995) 90-96
150. Khanna R., Burrows S.R., Argaet V., and Moss D.J. Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line. Int Immunol 6 (1994) 639-645
151. Wang D., Liebowitz D., Wang F., Gregory C., Rickinson A., Larson R., et al. Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol 62 (1988) 4173-4184
152. Wang F., Gregory C.D., Sample C., Rowe M., Liebowitz D., Murray R., et al. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol 64 (1990) 2309-2318
153. de Campos-Lima P.O., Torsteinsdottir S., Cuomo L., Klein G., Sulitzeanu D., and Masucci M.G. Antigen processing and presentation by EBV-carrying cell lines: cell-phenotype dependence and influence of the EBV-encoded LMP1. Int J Cancer 53 (1993) 856-862
154. Paludan C., Bickham K., Nikiforow S., Tsang M.L., Goodman K., Hanekom W.A., et al. Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells. J Immunol 169 (2002) 1593-1603
155. Taylor G.S., Long H.M., Haigh T.A., Larsen M., Brooks J., and Rickinson A.B. A role for intercellular antigen transfer in the recognition of EBV-transformed B cell lines by EBV nuclear antigen-specific CD4+ T cells. J Immunol 177 (2006) 3746-3756
156. Fu T., Voo K.S., and Wang R.F. Critical role of EBNA1-specific CD4+ T cells in the control of mouse Burkitt lymphoma in vivo. J Clin Invest 114 (2004) 542-550
157. Moormann A.M., Heller K.N., Chelimo K., Embury P., Ploutz-Snyder R., Otieno J.A., et al. Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responses. Int J Cancer 124 (2009) 1721-1726
158. Sabapathy K., and Nam S.Y. Defective MHC class I antigen surface expression promotes cellular survival through elevated ER stress and modulation of p53 function. Cell Death Differ 15 (2008) 1364-1374
159. Chen F., Zou J.-Z., di Rienzo L., Winberg G., Hu L.-F., Klein E., et al. A subpopulation of latently EBV infected B-cells resemble Burkitt's lymphoma (BL) cells in expressing EBNA1 but not EBNA2 or LMP1. J Virol 69 (1995) 3752-3758
160. Tierney R.J., Steven N., Young L.S., and Rickinson A.B. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol 68 (1994) 7374-7385
161. Qu L., and Rowe D.T. Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes. J Virol 66 (1992) 3715-3724
162. Hochberg D., Middeldorp J.M., Catalina M., Sullivan J.L., Luzuriaga K., and Thorley-Lawson D.A. Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci USA 101 (2004) 239-244
163. Babcock G.J., Decker L.L., Freeman R.B., and Thorley-Lawson D.A. Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J ExpMed 190 (1999) 567-576
164. Babcock G.J., Decker L.L., Volk M., and Thorley-Lawson D.A. EBV persistence in memory B cells in vivo. Immunity 9 (1998) 395-404
165. Ernberg I., Falk K., Minarovits J., Busson P., Tursz T., Masucci M.G., et al. The role of methylation in the phenotype-dependent modulation of Epstein-Barr nuclear antigen 2 and latent membrane protein genes in cells latently infected with Epstein-Barr virus. J Gen Virol 70 (1989) 2989-3002
166. Masucci M.G., Contreras-Salazar B., Ragnar E., Falk K., Minarovits J., Ernberg I., et al. 5-Azacytidine up-regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt's lymphoma line Rael. J Virol 63 (1989) 3135-3141
167. Allday M.J., Kundu D., Finerty S., and Griffin B.E. CpG methylation of viral DNA in EBV-associated tumours. Int J Cancer 45 (1990) 1125-1130
168. Minarovits J., Hu L.F., Minarovits-Kormuta S., Klein G., and Ernberg I. Sequence-specific methylation inhibits the activity of the Epstein-Barr virus LMP 1 and BCR2 enhancer-promoter regions. Virology 200 (1994) 661-667
169. Tierney R.J., Kirby H.E., Nagra J.K., Desmond J., Bell A.I., and Rickinson A.B. Methylation of transcription factor binding sites in the Epstein-Barr virus latent cycle promoter Wp coincides with promoter down-regulation during virus-induced B-cell transformation. J Virol 74 (2000) 10468-10479
170. Elliott J., Goodhew E.B., Krug L.T., Shakhnovsky N., Yoo L., and Speck S.H. Variable methylation of the Epstein-Barr virus Wp EBNA gene promoter in B-lymphoblastoid cell lines. J Virol 78 (2004) 14062-14065
171. Hutchings I.A., Tierney R.J., Kelly G.L., Stylianou J., Rickinson A.B., and Bell A.I. Methylation status of the Epstein-Barr virus (EBV) BamHI W latent cycle promoter and promoter activity: analysis with novel EBV-positive Burkitt and lymphoblastoid cell lines. J Virol 80 (2006) 10700-10711
172. Klein E., Teramoto N., Gogolak P., Nagy N., and Bjorkholm M. LMP-1, the Epstein-Barr virus-encoded oncogene with a B cell activating mechanism similar to CD40. Immunol Lett 68 (1999) 147-154
173. Walls E.V., Doyle M.G., Patel K.K., Allday M.J., Catovsky D., and Crawford D.H. Activation and immortalization of leukaemic B cells by Epstein-Barr virus. Int J Cancer 44 (1989) 846-853
174. Kis L.L., Nishikawa J., Takahara M., Nagy N., Matskova L., Takada K., et al. In vitro EBV-infected subline of KMH2, derived from Hodgkin lymphoma, expresses only EBNA-1, while CD40 ligand and IL-4 induce LMP-1 but not EBNA-2. Int J Cancer 113 (2005) 937-945
175. Baumforth K.R., Flavell J.R., Reynolds G.M., Davies G., Pettit T.R., Wei W., et al. Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells. Blood 106 (2005) 2138-2146
176. Ressing M.E., Horst D., Griffin B.D., Tellam J., Zuo J., Khanna R., et al. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products. Semin Cancer Biol 18 (2008) 397-408
177. Williams H., McAulay K., Macsween K.F., Gallacher N.J., Higgins C.D., Harrison N., et al. The immune response to primary EBV infection: a role for natural killer cells. Br J Haematol 129 (2005) 266-274
178. Pappworth I.Y., Wang E.C., and Rowe M. The switch from latent to productive infection in Epstein-Barr virus infected B cells is associated with sensitization to NK cell killing. J Virol 81 (2007) 474-482
179. Gregory C.D., Dive C., Henderson S., Smith C., Williams G.T., Gordon J., et al. Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature 349 (1991) 612-614
180. Wang S., Rowe M., and Lundgren E. Expression of the Epstein-Barr virus transforming protein LMP1 causes a rapid and transient stimulation of the Bcl-2 homologue Mcl-1 levels in B cell lines. Cancer Res 56 (1996) 4610-4613
181. D'Souza B., Rowe M., and Walls D. The bfl-1 gene is transcriptionally upregulated by the Epstein-Barr virus oncoprotein LMP1, and its expression promotes the survival of a Burkitt's lymphoma cell line. J Virol 74 (2000) 6652-6658
182. Pegman P.M., Smith S.M., D'Souza B.N., Loughran S.T., Maier S., Kempkes B., et al. Epstein-Barr virus nuclear antigen 2 trans-activates the cellular antiapoptotic bfl-1 gene by a CBF1/RBPJ{kappa}-dependent pathway. J Virol 80 (2006) 8133-8144
183. Caldwell R.G., Brown R.C., and Longnecker R. Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmLMP2A transgenic mice. J Virol 74 (2000) 1101-1113
184. Kurth J., Spieker T., Wustrow J., Strickler G.J., Hansmann L.M., Rajewsky K., et al. EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency. Immunity 13 (2000) 485-495